Yifeng Pharmacy Chain Co., Ltd.

SHSE:603939 Stock Report

Market Cap: CN¥31.4b

Yifeng Pharmacy Chain Future Growth

Future criteria checks 2/6

Yifeng Pharmacy Chain is forecast to grow earnings and revenue by 17.4% and 14.9% per annum respectively. EPS is expected to grow by 18.4% per annum. Return on equity is forecast to be 19.7% in 3 years.

Key information

17.4%

Earnings growth rate

18.4%

EPS growth rate

Consumer Retailing earnings growth45.0%
Revenue growth rate14.9%
Future return on equity19.7%
Analyst coverage

Good

Last updated09 Dec 2024

Recent future growth updates

Recent updates

Returns On Capital At Yifeng Pharmacy Chain (SHSE:603939) Have Stalled

Dec 12
Returns On Capital At Yifeng Pharmacy Chain (SHSE:603939) Have Stalled

We Like The Quality Of Yifeng Pharmacy Chain's (SHSE:603939) Earnings

Nov 06
We Like The Quality Of Yifeng Pharmacy Chain's (SHSE:603939) Earnings

The Market Lifts Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Shares 28% But It Can Do More

Sep 27
The Market Lifts Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Shares 28% But It Can Do More

Investors Met With Slowing Returns on Capital At Yifeng Pharmacy Chain (SHSE:603939)

Jul 29
Investors Met With Slowing Returns on Capital At Yifeng Pharmacy Chain (SHSE:603939)

Slammed 27% Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Screens Well Here But There Might Be A Catch

Jun 20
Slammed 27% Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) Screens Well Here But There Might Be A Catch

Yifeng Pharmacy Chain (SHSE:603939) Seems To Use Debt Rather Sparingly

May 24
Yifeng Pharmacy Chain (SHSE:603939) Seems To Use Debt Rather Sparingly

Yifeng Pharmacy Chain's (SHSE:603939) Solid Earnings Are Supported By Other Strong Factors

May 06
Yifeng Pharmacy Chain's (SHSE:603939) Solid Earnings Are Supported By Other Strong Factors

Is Now The Time To Put Yifeng Pharmacy Chain (SHSE:603939) On Your Watchlist?

Apr 13
Is Now The Time To Put Yifeng Pharmacy Chain (SHSE:603939) On Your Watchlist?

Market Participants Recognise Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Earnings

Mar 28
Market Participants Recognise Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Earnings

Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Intrinsic Value Is Potentially 100% Above Its Share Price

Mar 13
Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) Intrinsic Value Is Potentially 100% Above Its Share Price

Earnings and Revenue Growth Forecasts

SHSE:603939 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202633,5682,2983,5924,41616
12/31/202528,7391,8913,0663,81017
12/31/202424,2071,5852,0342,78812
9/30/202423,9191,5234,2875,084N/A
6/30/202423,6441,5054,2615,038N/A
3/31/202423,2931,4823,1733,985N/A
12/31/202322,5881,4123,8844,624N/A
9/30/202322,4271,4373,9894,494N/A
6/30/202321,8431,3913,6904,235N/A
3/31/202321,0041,3304,0374,561N/A
12/31/202219,8861,2623,3333,920N/A
9/30/202217,7361,0162,0902,792N/A
6/30/202216,7309601,5722,265N/A
3/31/202215,8459191,4002,203N/A
12/31/202115,3268881,3222,150N/A
9/30/202114,6468671,6702,381N/A
6/30/202114,1988471,7102,434N/A
3/31/202113,7267981,8122,486N/A
12/31/202013,1457441,7472,330N/A
9/30/202012,3246981,4901,994N/A
6/30/202011,5216379141,404N/A
3/31/202010,8555837431,203N/A
12/31/201910,276544504963N/A
9/30/20199,636526399774N/A
6/30/20198,968499435768N/A
3/31/20197,900463344604N/A
12/31/20186,913416267511N/A
9/30/20186,054402172394N/A
6/30/20185,562384N/A359N/A
3/31/20185,211345N/A345N/A
12/31/20174,807314N/A317N/A
9/30/20174,480285N/A205N/A
6/30/20174,210267N/A193N/A
3/31/20173,978241N/A161N/A
12/31/20163,734224N/A140N/A
9/30/20163,540210N/A207N/A
6/30/20163,305200N/A195N/A
3/31/20163,040187N/A160N/A
12/31/20152,846176N/A182N/A
9/30/20152,615169N/A229N/A
6/30/20152,492161N/A192N/A
3/31/20152,373150N/A235N/A
12/31/20142,230141N/A212N/A
12/31/20131,80499N/A157N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603939's forecast earnings growth (17.4% per year) is above the savings rate (2.8%).

Earnings vs Market: 603939's earnings (17.4% per year) are forecast to grow slower than the CN market (25.8% per year).

High Growth Earnings: 603939's earnings are forecast to grow, but not significantly.

Revenue vs Market: 603939's revenue (14.9% per year) is forecast to grow faster than the CN market (13.8% per year).

High Growth Revenue: 603939's revenue (14.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603939's Return on Equity is forecast to be low in 3 years time (19.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:48
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yifeng Pharmacy Chain Co., Ltd. is covered by 25 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ethan CuiBofA Global Research
Hao WuChasing Securities
Qianyi LiChina International Capital Corporation Limited